



Attenuating Ketamine-Induced Nephrotoxicity with *Bryophyllum pinnatum* Extract: Biochemical and Histological Investigation

Precious Ojo Uahomo ^{a*} and Joshua Charles Isirima ^a

^a Department of Pharmacology, Faculty of Basic Clinical Sciences, University of Port Harcourt, Choba, Rivers State, Nigeria.

Authors' contributions

This work was carried out in collaboration between both authors. Author JCI designed the study, performed the statistical analysis, and wrote the study protocol. Author POJ carried out the experiment, wrote the first draft of the manuscript, managed the analyses of the study, and the literature searches. Both authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/jocamr/2025/v26i1612>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/129155>

Original Research Article

Received: 28/10/2024

Accepted: 30/12/2024

Published: 04/01/2025

ABSTRACT

Background: Ketamine, a widely used anesthetic agent, has been shown to induce nephrotoxicity, characterized by increased kidney function markers and structural damage. Despite its therapeutic applications, the adverse effects of ketamine on the kidneys necessitate the exploration of potential protective agents. *Bryophyllum pinnatum* (*B. pinnatum*), an herbal plant with a long history of medicinal use, has demonstrated various therapeutic properties, including antioxidant, anti-inflammatory, and nephroprotective effects. However, its role in mitigating ketamine-induced kidney damage remains inadequately explored.

*Corresponding author: E-mail: uahomoprecious1@gmail.com;

Methods: Sixty male Wistar rats were assigned to six groups. Group 1 served as the control, while Group 2 received ketamine (20 mg/kg) for 7 days to induce renal toxicity. Groups 3-6 were treated with ketamine plus different doses of *B. pinnatum* extract (50, 100, 200 mg/kg) for 21 days. Biochemical markers, including blood urea nitrogen (BUN), creatinine, urea, sodium (Na), and potassium (K), were measured, and histopathological evaluations were conducted on kidney tissues.

Results: Ketamine administration significantly increased BUN (11.50 ± 0.17 mg/dL), creatinine (100.00 ± 2.89 μ mol/L), urea (43.00 ± 2.08 mg/dL), Na (164.00 ± 4.16 mmol/L), and K (2.83 ± 0.34 mmol/L) compared to controls ($p < 0.05$). Treatment with *B. pinnatum* at doses of 100 and 200 mg/kg significantly reduced these biomarkers, with the highest dose showing values near control levels (BUN: 5.33 ± 0.24 mg/dL, creatinine: 64.67 ± 4.26 μ mol/L, urea: 12.23 ± 0.15 mg/dL, Na: 131.00 ± 0.58 mmol/L, K: 1.10 ± 0.07 mmol/L, $p < 0.05$). Histologically, *B. pinnatum* treatment attenuated ketamine-induced renal damage, with marked improvements in tissue architecture.

Conclusion: *B. pinnatum* exhibited significant nephroprotective effects, as evidenced by the reduction of kidney function biomarkers and improved histological features, suggesting its potential as a therapeutic agent in managing ketamine-induced renal toxicity.

Keywords: Ketamine; nephrotoxicity; *Bryophyllum pinnatum*; nephroprotective effects; kidney function biomarkers; histopathology.

1. INTRODUCTION

The kidney is a vital organ responsible for essential functions such as filtration of blood, excretion of metabolic waste, regulation of electrolytes, maintenance of fluid balance, and production of hormones like erythropoietin and renin, which play critical roles in hematopoiesis and blood pressure regulation, respectively (Wandile, 2023; Badro, 2023). Its intricate architecture and functionality make it susceptible to damage from various pathological conditions. Injuries or diseases affecting the kidney can significantly impair these functions, potentially leading to life-threatening complications such as chronic kidney disease, acute kidney injury, or even systemic dysfunctions (Jha et al., 2013; Nsengiyumva et al., 2018).

Pathologies of the kidney may arise due to direct insults, secondary to systemic diseases, or as adverse effects of drugs used to manage other conditions. Unexpected kidney and liver injuries are often observed in cases of drug abuse or excessive use of medications. Notably, some drugs administered for therapeutic purposes may cause collateral damage to other organs, particularly the liver, owing to shared metabolic pathways. One such drug is ketamine, which is widely used but increasingly recognized for its toxic effects on the liver and kidneys (Morgan et al., 2012; Ezquerro-Romano et al., 2018; Strous et al., 2022; Geoffrion, 2024).

Ketamine is a general anesthetic that produces a dissociative state at subanesthetic doses,

characterized by depersonalization and derealization (Cheung & Yew, 2019; Choudhury et al., 2021; Ji et al., 2022). As a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, it exerts its effects through inhibition of NMDA receptors, resulting in altered perception and pain modulation (Liu et al., 2019; Uahomo et al., 2023; Egunlusi & Joubert, 2024). Ketamine is metabolized in the liver to its active metabolite, norketamine, which is subsequently excreted through the renal system. Although ketamine was developed as a safer alternative to phencyclidine, its prolonged use in high doses has raised concerns due to associated organ toxicities. Notably, ketamine has been linked to conditions such as ketamine-associated cystitis, characterized by inflammation and ulceration of the bladder wall, which may extend to the ureters and kidneys (Morgan & Curran, 2012; Strous et al., 2022). Additionally, ketamine has been documented to cause hepatotoxicity, emphasizing the need for careful monitoring of its use (Anderson et al., 2022; Chan et al., 2022; Yoo et al., 2024).

Maintaining kidney health is paramount, as renal pathologies resulting from injuries such as glomerulonephritis, ischemia-reperfusion injury, or drug-induced nephrotoxicity can have severe systemic consequences (Malek & Nematbakhsh, 2015; Liu et al., 2018; Boyer et al., 2022). Given the dual susceptibility of the kidney and liver to damage in cases of ketamine abuse, there is an urgent need for therapeutic strategies to mitigate these effects and restore normal organ function.

To ensure the healthy functioning of the kidneys and liver, researchers have increasingly turned to herbal remedies for their potential to reverse drug-induced injuries. Studies have demonstrated that several medicinal plants possess nephroprotective and hepatoprotective properties, effectively mitigating ketamine-induced organ damage. For instance, plants like *Hypoestes rosea* (Ogregade et al., 2024), *Curcuma longa* (Akinyemi et al., 2018; Alkuraishy et al., 2019; Lee et al., 2022; Wanjala et al., 2023), *Glycyrrhiza glabra* (Basist et al., 2022), and *Phyllanthus niruri* (Pahmi et al., 2023), have been reported to exhibit antioxidant, anti-inflammatory, and regenerative properties, reducing oxidative stress and improving organ function in experimental models.

One plant gaining attention for its protective effects against drug-induced toxicities is *Bryophyllum pinnatum* (*B. pinnatum*). Commonly known as the "life plant," *B. pinnatum* is a perennial succulent with a rich history of ethnomedicinal use (Akindele et al., 2022; Dhumane et al., 2024). Its phytochemical composition includes bioactive compounds such as flavonoids, alkaloids, triterpenoids, and phenolic acids, which have been shown to confer anti-inflammatory, antioxidant, and cytoprotective properties. Pharmacological studies have demonstrated the plant's ability to mitigate oxidative stress, reduce inflammation, and promote tissue regeneration, making it a promising candidate for the management of ketamine-induced liver and kidney injuries (Dhumane et al., 2024).

This study seeks to investigate the biochemical and histological improvements in ketamine-induced liver injury in Wistar rats via the administration of *B. pinnatum* leaf extract. By exploring the protective and reparative effects of this medicinal plant, the study aims to provide new insights into its therapeutic potential for managing drug-induced organ toxicities.

2. MATERIALS AND METHODS

2.1 Experimental Animals

Sixty male Wistar rats, weighing between 180 and 200 grams, were procured from the Animal House of the Department of Pharmacology, Faculty of Basic Clinical Sciences, University of Port Harcourt. The animals were housed in clean, disinfected wooden cages lined with

sawdust bedding, maintained under controlled conditions of a 12-hour light/dark cycle, 50–60% humidity, and a temperature of approximately 30°C. Prior to the commencement of the experiment, the rats were acclimatized for two weeks with unrestricted access to clean water and standard animal feed.

2.2 Chemicals and Plant Used

Fresh leaves of *B. pinnatum* were collected from the area behind the Ofrima Building within the Abuja Park of the University of Port Harcourt. The plant was identified and authenticated by Dr. Edwin Nwosu of the Department of Plant Science and Biotechnology, Faculty of Sciences, University of Port Harcourt, and was assigned the voucher number UPH/V/1308. Ketamine and risperidone were procured from Alpha Pharmacy and Stores on NTA Road, Port Harcourt, Rivers State, Nigeria.

2.3 Preparation of *B. pinnatum* Extract

The plant tissue homogenization technique, as detailed by Pandey and Tripathi (2014), was employed to extract fresh juice from the leaves of *B. pinnatum*. Fresh leaves were finely ground using a blender, and the juice was subsequently extracted and filtered through a clean white handkerchief, following the methodology described by Das et al. (2010). The extracted juice was carefully collected into clean reagent bottles and stored under refrigeration to ensure preservation.

2.4 Dose Selection

The doses of ketamine (20 mg/kg) and risperidone (0.5 mg/kg) used in this study were based on recommendations by Monte et al. (2013) and Ben-Azu et al. (2016), respectively. Sub-lethal doses of *B. pinnatum* crude extract (50, 100, 200 mg/kg body weight) following guidelines from Salahdeen and Yemitan (2006), and were administered in 0.1 ml, 0.2 ml and 0.4 ml volume respectively after a preliminary dose-determination experiment to determine the weight (mg/mL) of *B. pinnatum*.

2.5 Experimental Design

The protocol was designed and modified based on the established method by Monte et al. (2013) and Uahomo and Isirima et al. (2024). The research was conducted in two distinct phases;

Table 1. Intervention phase experimental design

Group	Identity	No. of Rats	Treatment Protocol
Group 1	Control	9	2ml of normal saline once daily for 21 days
Group 2	Ketamine	9	Received 20 mg/kg ketamine I.P. once daily for 21 days
Group 3	Risperidone	9	Received 0.5 mg/kg risperidone orally once daily for 21 days
Group 4	BP50	9	Received 50 mg/kg body weight of <i>B. pinnatum</i> extract
Group 5	BP100	9	Received 100 mg/kg body weight of <i>B. pinnatum</i> extract
Group 6	BP200	9	Receive 200 mg/kg body weight of <i>B. pinnatum</i> extract

- **Induction phase:** The sixty (60) animals were randomly assigned to two groups. Group 1 consisted of 12 animals (n=12) and was administered 2ml of distilled water once daily for 7 days. On the other hand, Group 2 comprised 48 animals (n = 48) and received a sub-anesthetic dose of 20mg/kg ketamine once daily intraperitoneally (I.P.) for 7 days. Three (3) animals were sacrificed from each group on the 7th day, and blood samples, as well as liver tissues, were collected for biochemical and histological examinations aimed at establishing the toxicity in the animal model.
- **Intervention Phase:** Group assignments for the intervention phase (Table 1) include controls, ketamine-only, risperidone-treated, and three doses of *B. pinnatum*. Treatments lasted 21 days following a 7-day induction period. Risperidone and doses of *B. pinnatum* were administered by oral gavage.

2.6 Collection of Blood and Tissue Sample

Twenty-four hours following the treatments on the 8th, 15th, and 22nd days of the experimental period, the animals were anesthetized using diethyl ether and subsequently euthanized. Blood samples were collected through cardiac puncture, while kidney tissues were harvested for biochemical and histological evaluations.

2.7 Biochemical Analysis

Kidney function biomarkers were assessed to evaluate the effects of *B. pinnatum* leaf extract on renal health in Wistar rats subjected to ketamine-induced toxicity. These biomarkers included Sodium (Na), which plays a crucial role in fluid balance and neuromuscular function, and Potassium (K), essential for maintaining cellular function and membrane potential. Calcium (Ca) levels were analyzed, reflecting kidney

involvement in calcium homeostasis. Urea and Creatinine levels served as key indicators of glomerular filtration rate (GFR) and overall renal excretory function. Albumin levels were also measured, as they serve as a critical marker of protein leakage and kidney function integrity. Finally, Blood Urea Nitrogen (BUN), which reflects protein metabolism and kidney clearance ability, was measured to provide further insight into renal function under ketamine-induced stress and its potential amelioration by *B. pinnatum*

2.8 Kidney Function Biomarkers Assay

Kidney function biomarkers were analyzed using validated methods: serum sodium and potassium levels were determined using the flame photometric method as described by Maruna and Trinder (1958); calcium was assessed using the O-Cresolphthalein Complexone (OCPC) method following Morin (1974); albumin was determined using the Bromocresol Green (BCG) dye-binding method as described by Doumas et al. (1971); creatinine levels were determined by the Jaffe reaction as outlined by Bonsnes and Taussky (1945); urea concentration was measured enzymatically using the Urease-Glutamate Dehydrogenase (GLDH) method described by Weatherburn (1967); and blood urea nitrogen (BUN) was calculated from urea levels using established conversion factors consistent with Hosten (1990).

$$BUN (mg/dL) = Urea (mg/dL) \times 0.467$$

2.9 Histopathological Examination

The animals were anesthetized with diethyl ether and subsequently dissected aseptically to remove the kidney tissues. The tissues were then transferred into 10% formalin and carefully trimmed to a thickness of 2mm to 4mm to facilitate the penetration of the fixative. The kidney tissues were processed through several stages, including fixation, dehydration, clearing, impregnation, embedding, sectioning, and staining with hematoxylin and eosin (H&E), followed by mounting. These standard tissue

processing methods were adapted from the protocols outlined by Baker (1945) and Isirima and Uahomo (2023).

2.10 Method of Data Analysis

The data collected were analyzed using the Statistical Package for Social Sciences (IBM SPSS, Version 26.0). Descriptive statistics, such as means and standard error of mean (SEM), were used to summarize the data from the experimental groups. Inferential statistical tests, including one-way analysis of variance (ANOVA) or t-tests, were conducted to assess differences between groups. Post-hoc tests, such as the Dunnett (2-sided) test, were employed to compare the study groups and identify statistically significant differences, with significance set at $p < 0.05$.

3. RESULTS

3.1 Effect of Ketamine, Risperidone and *B. pinnatum* on Biomarkers of the Kidney

Ketamine administration significantly disrupted kidney function, as evidenced by elevated BUN (11.50 ± 0.17 mg/dL vs. control: 6.77 ± 0.15 mg/dL,

$p < 0.05$), creatinine (100.00 ± 2.89 μ mol/L vs. control: 69.00 ± 2.08 μ mol/L, $p < 0.05$), urea (43.00 ± 2.08 mg/dL vs. control: 26.00 ± 1.15 mg/dL, $p < 0.05$), sodium (164.00 ± 4.16 mmol/L vs. control: 139.00 ± 0.58 mmol/L, $p < 0.05$), and potassium (2.83 ± 0.34 mmol/L vs. control: 1.20 ± 0.06 mmol/L, $p < 0.05$), while significantly reducing calcium (0.77 ± 0.18 mmol/L vs. control: 2.50 ± 0.06 mmol/L, $p < 0.05$) and albumin (2.33 ± 0.24 g/dL vs. control: 4.10 ± 0.06 g/dL, $p < 0.05$). Risperidone treatment partially mitigated these effects, with intermediate BUN (8.77 ± 0.15 mg/dL), creatinine (85.00 ± 1.73 μ mol/L), urea (34.00 ± 1.15 mg/dL), sodium (140.67 ± 0.88 mmol/L), potassium (3.50 ± 0.12 mmol/L), calcium (2.43 ± 0.09 mmol/L), and albumin (4.10 ± 0.06 g/dL) levels by week 3 ($p < 0.05$). Treatment with *B. pinnatum* demonstrated dose-dependent amelioration of ketamine-induced alterations, with the high-dose group (200 mg/kg) restoring BUN (5.33 ± 0.24 to 5.73 ± 0.49 mg/dL), creatinine (64.67 ± 4.26 μ mol/L), urea (12.23 ± 0.15 to 23.33 ± 0.88 mg/dL), sodium (131.00 ± 0.58 mmol/L), potassium (0.50 ± 0.05 to 0.93 ± 0.09 mmol/L), calcium (2.43 ± 0.12 to 3.43 ± 0.15 mmol/L), and albumin (3.57 ± 0.23 to 4.47 ± 0.03 g/dL) levels closer to or exceeding control values ($p < 0.05$) (see Table 2 to 8).

Table 2. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on BUN (mmol/L) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	$6.77 \pm 0.15\#$	$6.77 \pm 0.15\#$	$6.80 \pm 0.15\#$
20mg/kg Ketamine	$11.50 \pm 0.17^*$	$11.50 \pm 0.17^*$	$11.50 \pm 0.17^*$
0.5mg/kg Risperidone	$6.77 \pm 0.15\#$	7.50 ± 0.17	8.77 ± 0.15
50mg/kg <i>B. pinnatum</i>	$5.50 \pm 0.17\#$	8.70 ± 0.12	6.83 ± 0.52
100mg/kg <i>B. pinnatum</i>	$6.23 \pm 0.15\#$	7.50 ± 0.68	$5.53 \pm 0.72\#$
200mg/kg <i>B. pinnatum</i>	$5.33 \pm 0.24\#$	$6.40 \pm 0.75\#$	$5.73 \pm 0.49\#$

Values are presented in Mean \pm SEM; $n=3$, $*$ =means values are statistically significant at $p < 0.05$ when compared to the control values; $\#$ =means values are statistically significant at $p < 0.05$ when compared to group 2 (ketamine-induced) values

Table 3. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on Creatinine (μ mol/L) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	$69.00 \pm 2.08\#$	$69.00 \pm 2.08\#$	$69.00 \pm 2.08\#$
20mg/kg Ketamine	$100.00 \pm 2.89^*$	$100.00 \pm 2.89^*$	$100.00 \pm 2.89^*$
0.5mg/kg Risperidone	$79.00 \pm 2.08^*\#$	$82.00 \pm 2.31^*\#$	$85.00 \pm 1.73^*\#$
50mg/kg <i>B. pinnatum</i>	$74.33 \pm 2.33^*\#$	$72.00 \pm 4.62^*\#$	$75.00 \pm 10.15^*\#$
100mg/kg <i>B. pinnatum</i>	$75.00 \pm 6.81^*\#$	$78.67 \pm 1.76^*\#$	$67.00 \pm 4.58\#$
200mg/kg <i>B. pinnatum</i>	$69.00 \pm 3.79\#$	$70.67 \pm 7.06\#$	$64.67 \pm 4.26\#$

Values are presented in Mean \pm SEM; $n=3$, $*$ =mean values are statistically significant at $p < 0.05$ when compared to the control values; $\#$ =means values are statistically significant at $p < 0.05$ when compared to group 2 (ketamine-induced) values

Table 4. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on Urea ($\mu\text{mol/L}$) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	26.00 \pm 1.15#	26.00 \pm 1.15#	26.00 \pm 1.15#
20mg/kg Ketamine	43.00 \pm 2.08*	43.00 \pm 2.08*	43.00 \pm 2.08*
0.5mg/kg Risperidone	10.10 \pm 0.21*#	34.00 \pm 1.15*#	27.00 \pm 3.61#
50mg/kg <i>B. pinnatum</i>	11.50 \pm 1.85*#	32.00 \pm 1.15*#	25.00 \pm 1.73#
100mg/kg <i>B. pinnatum</i>	14.00 \pm 1.89*#	31.33 \pm 2.40*#	23.67 \pm 2.33#
200mg/kg <i>B. pinnatum</i>	12.23 \pm 0.15*#	27.33 \pm 2.40#	23.33 \pm 0.88#

Values are presented in Mean \pm SEM; n=3, *=means values are statistically significant at $p<0.05$ when compared to the control values; # =means values are statistically significant at $p<0.05$ when compared to group 2 (ketamine-induced) values

Table 5. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on Sodium (Na) (mmol/L) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	139.00 \pm 0.58#	139.00 \pm 0.58#	139.00 \pm 0.58#
20mg/kg Ketamine	164.00 \pm 4.16*	164.00 \pm 4.16*	164.00 \pm 4.16*
0.5mg/kg Risperidone	140.00 \pm 1.15#	136.00 \pm 0.58#	140.67 \pm 0.88#
50mg/kg <i>B. pinnatum</i>	138.00 \pm 0.115#	140.00 \pm 0.58#	139.67 \pm 1.45#
100mg/kg <i>B. pinnatum</i>	138.67 \pm 1.76#	137.00 \pm 0.58#	140.00 \pm 0.58#
200mg/kg <i>B. pinnatum</i>	136.00 \pm 1.15#	134.00 \pm 0.58#	131.00 \pm 0.58#

Values are presented in Mean \pm SEM; n=3, *=means values are statistically significant at $p<0.05$ when compared to the control values; # =means values are statistically significant at $p<0.05$ when compared to group 2 (ketamine-induced) values

Table 6. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on Potassium (K) (mmol/L) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	1.20 \pm 0.06#	1.20 \pm 0.06#	1.20 \pm 0.06#
20mg/kg Ketamine	2.83 \pm 0.34*	2.83 \pm 0.34*	2.83 \pm 0.34*
0.5mg/kg Risperidone	1.10 \pm 0.06#	0.90 \pm 0.06#	3.50 \pm 0.12*
50mg/kg <i>B. pinnatum</i>	1.30 \pm 0.06#	1.10 \pm 0.05#	3.13 \pm 0.15*
100mg/kg <i>B. pinnatum</i>	1.30 \pm 0.115#	0.80 \pm 0.06#	3.27 \pm 0.18*
200mg/kg <i>B. pinnatum</i>	1.23 \pm 0.09#	0.50 \pm 0.05*#	0.93 \pm 0.09#

Values are presented in Mean \pm SEM; n=3, *=mean values are statistically significant at $p<0.05$ when compared to the control values; # =means values are statistically significant at $p<0.05$ when compared to group 2 (ketamine-induced) values

Table 7. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on Calcium (Ca) (mmol/L) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	2.50 \pm 0.06#	2.50 \pm 0.06#	2.50 \pm 0.06#
20mg/kg Ketamine	0.77 \pm 0.18*	0.77 \pm 0.18*	0.77 \pm 0.18*
0.5mg/kg Risperidone	2.47 \pm 0.09#	2.80 \pm 0.06#	2.43 \pm 0.09#
50mg/kg <i>B. pinnatum</i>	2.40 \pm 0.12#	2.70 \pm 0.06#	2.67 \pm 0.09#
100mg/kg <i>B. pinnatum</i>	2.40 \pm 0.06#	3.00 \pm 0.06#	2.60 \pm 0.17#
200mg/kg <i>B. pinnatum</i>	2.43 \pm 0.12#	3.30 \pm 0.06#	3.43 \pm 0.15#

Values are presented in Mean \pm SEM; n=3, *=means values are statistically significant at $p<0.05$ when compared to the control values; # =means values are statistically significant at $p<0.05$ when compared to group 2 (ketamine-induced) values

Table 8. Result of the effect of Ketamine and crude extract doses of *Bryophyllum pinnatum* on Albumin (ALB) (g/dl) in Wistar rats

Groups	Week 1	Week 2	Week 3
Control	4.10±0.06#	4.10±0.06#	4.10±0.06#
20mg/kg Ketamine	2.33±0.24*	2.33±0.24*	2.33±0.24*
0.5mg/kg Risperidone	4.23±0.15#	4.40±0.06#	4.10±0.06#
50mg/kg <i>B. pinnatum</i>	4.00±0.12#	4.30±0.06#	3.90±0.06#
100mg/kg <i>B. pinnatum</i>	4.17±0.20#	4.60±0.06#	4.07±0.09#
200mg/kg <i>B. pinnatum</i>	3.57±0.23	4.90±0.06#	4.47±0.03#

Values are presented in Mean ± SEM; n=3, *=means values are statistically significant at p<0.05 when compared to the control values; # =means values are statistically significant at p<0.05 when compared to group 2 (ketamine-induced) values




Fig. 1. Photomicrograph of the Kidney tissue across different treatment groups (H & E, x400) in week 1

(A1) normal microstructure with numerous renal tubules and connective tissue in the control group; (B1) abnormalities in the epithelial lining of distal convoluted tubules, congestion in renal blood vessels, and defined proximal convoluted tubules in ketamine-exposed animals treated with risperidone; (C1) hypertrophy of glomerular cells, distortion of renal tubules, and defined proximal convoluted tubules in ketamine-exposed animals treated with a low dose of *B. pinnatum*; (D1) dilatation and rupture of glomerular capillaries, oedematous glomerulus, and congestion in connective tissue space in animals treated with a moderate dose of *B. pinnatum*; (E1) ruptured glomerular capillaries, cellular degeneration, and distortion in distal convoluted tubules in animals treated with a high dose of *B. pinnatum*; (F1) ruptured glomerular capillaries, cellular degeneration, and mild fluid deposition in animals exposed to ketamine without treatment

3.2 The Effect of Ketamine, Risperidone and *B. pinnatum* on Kidney Histology

The histological assessment of kidney tissues across different experimental groups demonstrated varying degrees of structural alterations, depending on the treatment administered and the duration of exposure to ketamine.

In week 1, the normal control group displayed well-preserved renal tubules and connective tissue, while ketamine exposure at 20 mg/kg

without treatment caused ruptured glomerular capillaries, cellular degeneration, and disrupted renal tubules; treatment with risperidone at 0.5 mg/kg mitigated some damage but still showed congestion in renal blood vessels and epithelial abnormalities. *B. pinnatum* at 50 mg/kg caused glomerular hypertrophy and tubule disruption, 100 mg/kg led to dilatation and rupture of glomerular capillaries with fluid deposits, and 200 mg/kg resulted in extensive capillary rupture, cellular degeneration, and significant renal structural distortion.




Fig. 2. Photomicrograph of the Kidney tissue across different treatment groups (H & E, x400) in week 2

(A2) normal microstructure in the control group;

(B2) ruptured glomerular capillaries, glomerular oedema, and distortion in epithelial lining of distal convoluted tubules in ketamine-exposed animals treated with risperidone; (C2) cellular proliferation, hypertrophy, diffuse fluid accumulation in connective tissues, and dilated renal tubules in animals treated with a low dose of *B. pinnatum*;

(D2) ruptured glomerular capillaries, pronounced glomerular oedema, and fluid deposition in connective tissue spaces in animals treated with a moderate dose of *B. pinnatum*;

(E2) distortions in glomeruli, epithelial lining of distal convoluted tubules, and connective tissue abnormalities in animals treated with a high dose of *B. pinnatum*;

(F2) dilated glomerular capillaries, cellular proliferation, and hypertrophy in the epithelial lining of proximal and distal convoluted tubules in animals exposed to ketamine without treatment




Fig. 3. Photomicrograph of the Kidney tissue across different treatment groups (H & E, x400) in week 3

(A3) normal microstructure in the control group;
 (B3) distortion in glomerular cells, distortion in epithelial lining of distal convoluted tubules, and microstructural alterations in ketamine-exposed animals treated with risperidone; (C3) ruptured glomerular capillaries, cellular hypertrophy, and distortion in the epithelial lining of distal convoluted tubules in animals treated with a low dose of *B. pinnatum*; (D3) dilated glomerular capillaries, distorted connective tissue, and deposits in distal convoluted tubules in animals treated with a moderate dose of *B. pinnatum*; (E3) ruptured glomerular capillaries, deposits in proximal convoluted tubules, and congested renal blood vessels in animals treated with a high dose of *B. pinnatum*; (F3) proliferation and hypertrophy of glomerular cells, congested renal tubules, and disrupted microstructure in animals exposed to ketamine without treatment

In week 2, untreated ketamine exposure at 20 mg/kg caused severe structural damage with dilated glomerular capillaries, cellular proliferation, and hypertrophy in renal tubules; risperidone treatment at 0.5 mg/kg showed pronounced glomerular oedema and epithelial distortion. *B. pinnatum* treatment exhibited dose-dependent effects, with 50 mg/kg causing diffuse fluid accumulation, renal tubule dilation, and inflammation, 100 mg/kg exacerbating capillary

rupture and oedema with fluid deposits, and 200 mg/kg leading to distorted glomeruli and tubules with connective tissue abnormalities.

In week 3, ketamine exposure at 20 mg/kg without treatment led to glomerular cell proliferation, hypertrophy, and severe renal tubule congestion; risperidone treatment at 0.5 mg/kg showed persistent glomerular and epithelial distortions. *B. pinnatum* treatment

demonstrated dose-dependent responses, where 50 mg/kg caused glomerular capillary rupture, cellular hypertrophy, and epithelial disruption, 100 mg/kg led to glomerular capillary dilation, connective tissue distortion, and tubule deposits, and 200 mg/kg caused ruptured glomerular capillaries, proximal tubule deposits, and renal blood vessel congestion.

4. DISCUSSION

The present study aimed to evaluate the potential protective effects of *B. pinnatum* against ketamine-induced kidney injury in Wistar rats, focusing on both biochemical and histological markers of kidney function and structure. Ketamine, a commonly used anesthetic, is known to cause nephrotoxicity through its mechanisms of oxidative stress, tubular injury, and glomerular damage. Ketamine abuse has been linked to significant kidney damage and dysfunction, including chronic, often irreversible damage such as hydronephrosis, renal failure, shrunken urinary bladder, and hydroureteronephrosis, all affecting kidney function (Selby et al., 2008; Dibbur, 2021). Chronic use of ketamine can also cause structural damage to the urinary tract, including the bladder, ureters, and kidneys (Shung et al., 2021). While the exact mechanism of ketamine-induced kidney damage is not fully understood, it may involve direct effects of the drug or its metabolites, immunological reactions to contaminants, or interactions with other drugs of abuse (Selby et al., 2008). Symptoms of ketamine-induced kidney damage include burning micturition, incontinence, and recurrent urinary tract problems (Dibbur, 2021).

In this study, we assessed the biochemical effects of *B. pinnatum* on key kidney biomarkers, including blood urea nitrogen (BUN), creatinine, urea, sodium, potassium, calcium, and albumin. Additionally, we examined the histopathological changes in kidney tissues to further understand the impact of *B. pinnatum* on renal structure in the context of ketamine-induced damage.

The impact of *B. pinnatum* on various biochemical markers of kidney function was evident in the results of this study, where the administration of ketamine resulted in significant biochemical alterations, indicating renal dysfunction. Ketamine exposure notably increased BUN, creatinine, and urea levels, suggesting impaired renal filtration and excretion, a hallmark of nephrotoxicity. BUN and creatinine

are well-established biomarkers of kidney injury, and elevated levels of these parameters are commonly associated with renal impairment. Furthermore, ketamine caused a significant rise in sodium and potassium levels, reflecting disturbed electrolyte balance, which is often seen in renal injury due to reduced renal excretion capacity. The alteration in calcium and albumin levels also pointed to disrupted renal homeostasis. This observation is corroborated by Jang et al. (2017) and Vizgan et al. (2023), who reported that ketamine caused nephrotoxicity in rats, characterized by increased BUN, creatinine, and urea levels, and decreased calcium and albumin levels.

The significant increase in BUN, creatinine, urea, sodium, and potassium levels, along with the decrease in calcium and albumin levels induced by ketamine, suggests severe kidney dysfunction in Wistar rats. Elevated BUN and creatinine levels indicate impaired GFR, a critical marker of renal health, suggesting that the kidneys are not effectively filtering waste products from the blood. High urea levels further confirm compromised kidney function and potential accumulation of toxic metabolites (Selby et al., 2008; Jang et al., 2017; Demirkiran et al., 2019). Increased sodium and potassium levels point to disrupted electrolyte balance and impaired renal tubular function, potentially leading to conditions like hypernatremia and hyperkalemia, which can have severe systemic effects, including cardiovascular complications (Selby et al., 2008). The decrease in calcium levels could suggest altered calcium-phosphate metabolism, affecting bone health and neuromuscular function. Reduced albumin levels indicate impaired protein synthesis or increased protein loss due to damaged kidney structures, leading to issues like edema and compromised oncotic pressure (Ou et al., 2020; Manongi et al., 2022).

Herbal plants have been widely reported to exert nephroprotective effects through their rich antioxidant, anti-inflammatory, and cytoprotective properties, aiding in the amelioration of kidney damage caused by toxic agents. Treatment with *B. pinnatum* at both 100 mg/kg and 200 mg/kg doses significantly mitigated these biochemical changes, bringing the levels of BUN, creatinine, and urea closer to the control values. This is in line with previous studies that have shown the nephroprotective effects of *B. pinnatum*, possibly due to its antioxidant and anti-inflammatory properties (Andrade et al., 2020; Daniel et al., 2020; Namadina et al., 2020). The reduction in

sodium and potassium levels with *B. pinnatum* treatment suggests an improvement in renal function and electrolyte balance, which could be attributed to the plant's ability to modulate renal tubular transport and reduce cellular damage. The restoration of calcium and albumin levels further supports the protective effects of *B. pinnatum*, as both are critical biomarkers of kidney integrity and function.

The treatment with *B. pinnatum* demonstrated a dose-dependent response in mitigating ketamine-induced renal dysfunction, with the 200 mg/kg dose being the most effective in normalizing biochemical markers. Specifically, this high dose resulted in values of BUN, creatinine, and urea that closely approached those of the control group, indicating a robust restoration of kidney function. The medium dose (100 mg/kg) also significantly improved these markers, although to a slightly lesser extent than the higher dose.

The dose-dependent nephroprotective effects of *B. pinnatum* can be attributed to its diverse array of bioactive compounds such as flavonoids, phenolic compounds, alkaloids, triterpenoids, and bufadienolides. These compounds collectively contribute to its pharmacological actions by acting as potent antioxidants, reducing oxidative stress-induced damage to renal tissues. Furthermore, they possess anti-inflammatory properties that help mitigate inflammation associated with ketamine-induced nephrotoxicity. Previous research has demonstrated the nephroprotective activity of *B. pinnatum* against gentamicin-induced nephrotoxicity in Wistar rat kidneys, highlighting its antioxidant and radical scavenging properties (Shukla et al., 2014; Dighade et al., 2021). Furthermore, studies suggest that the plant's juice, known for its anti-cholinergic effects, effectively treats hyperactive bladder with fewer side effects compared to conventional drugs.

The histopathological findings from this study provided crucial insight into the structural effects of ketamine on kidney tissue and the potential ameliorative role of *B. pinnatum*. In the control group, the kidney tissue remained structurally intact, with well-preserved renal tubules and connective tissue. In contrast, ketamine treatment resulted in extensive kidney damage, characterized by ruptured glomerular capillaries, cellular degeneration, and disrupted renal tubules. These histopathological changes suggest profound nephrotoxicity, potentially due

to direct cellular toxicity or inflammatory responses leading to impaired renal function and structural integrity. Previous studies have reported similar findings, with Demirkiran et al. (2019) observing significant histopathological changes in renal tissue following ketamine exposure, including congestion. In their study, congestion was observed in the control group at a medium level, whereas the ketamine-treated group exhibited statistically lower congestion levels compared to the control group. Kasikara et al. (2021) also reported increased vascular congestion in the kidney of the ketamine group compared to the saline group, reinforcing the nephrotoxic effects of ketamine. Additionally, Yahyaei et al. (2024) described similar renal abnormalities, including ruptured glomerular capillaries, cellular proliferation, and hypertrophy in glomerular cells and renal tubules over a three-week exposure period to ketamine.

Risperidone, which was used as a positive control in this study, partially mitigated the ketamine-induced histological damage, but some abnormalities such as glomerular congestion and epithelial distortions were still evident. These findings suggest that risperidone might provide limited protection against ketamine-induced kidney injury, highlighting the need for more effective treatments.

The histological examination of *B. pinnatum*-treated rats revealed dose-dependent effects. The low-dose *B. pinnatum* (50 mg/kg) group exhibited moderate glomerular hypertrophy and tubule disruption, indicating some level of nephroprotective effect, though the damage was still evident. A more pronounced protective effects were observed with 100 mg/kg and 200 mg/kg dose treatment. The 200mg/kg treated group exhibited reduced capillary rupture, cellular degeneration, and renal structural distortion, and the renal tubules showed less disruption. Notably, the 200mg/kg *B. pinnatum* treatment closely resembled the control group in terms of renal tissue integrity, suggesting a significant reduction in ketamine-induced nephrotoxicity.

These histological observations correlate well with the biochemical data, where the high-dose *B. pinnatum* group showed the greatest improvements in kidney function. The protective effects can be attributed to the plant's bioactive compounds such as flavonoids, phenolic compounds, alkaloids, triterpenoids, and bufadienolides, which act as potent antioxidants and anti-inflammatory agents (Yadav et al., 2016;

Dighade et al., 2021; Selvakumar, 2022). These compounds help mitigate oxidative stress and inflammation, reducing cellular damage, hypertrophy, and structural distortions in renal tissues affected by ketamine-induced nephrotoxicity. Furthermore, *B. pinnatum*'s anti-inflammatory and cell-protective effects may promote tissue repair and regeneration, which could explain the structural improvements observed in the kidneys of treated rats.

The ethnomedicinal use of *B. pinnatum* has been supported by previous studies, confirming that its leaf extracts prevent renal calculi formation and ameliorate histological alterations in kidney tissues [59]. Moreover, Anadozie et al. (2018) demonstrated the nephroprotective effects of *B. pinnatum*, highlighting its ability to inhibit arginase II activity and mitigate oxidative damage induced by carbon tetrachloride (CCl₄) in rats. Furthermore, Hosomi et al. (2022) reported the safety of *B. pinnatum* mother tincture (MT) during pregnancy, showing no histological changes in maternal or fetal structures. Additionally, *B. pinnatum* has been shown to enhance kidney function by reducing glucose and creatinine levels.

5. CONCLUSION

The present study highlights the potential nephroprotective effects of *Bryophyllum pinnatum* in mitigating ketamine-induced kidney injury. Both biochemical and histological assessments indicate that *B. pinnatum*, particularly at higher doses, can attenuate renal dysfunction and preserve kidney structure. These findings suggest that *B. pinnatum* could be a promising candidate for the development of therapeutic strategies aimed at protecting the kidneys from nephrotoxic damage caused by substances such as ketamine. Further studies are needed to elucidate the precise mechanisms underlying the nephroprotective effects of *B. pinnatum* and to evaluate its potential clinical applications in the treatment of kidney diseases.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Authors hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The study was conducted in accordance with ethical guidelines established by the National Institutes of Health (NIH) for the ethical treatment of animals in research. Approval for the study protocol was obtained from the Research Ethics Committee of the University of Port Harcourt, Rivers State, Nigeria, under reference number UPH/CEREMAD/REC/MM91/076.

ACKNOWLEDGEMENT

We appreciate the research assistance from the Laboratory Technologists in the Department of Pharmacology and Animal House Unit in the course of this study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Akindele, A. J., Sowemimo, A., Agunbiade, F. O., et al. (2022). Bioprospecting for anti-COVID-19 interventions from African medicinal plants: A review. *Natural Product Communications*, 17(5). <https://doi.org/10.1177/1934578X221096968>
- Akinyemi, A. J., Faboya, O. L., Paul, A. A., Olayide, I., Faboya, O. A., & Oluwasola, T. A. (2018). Nephroprotective effect of essential oils from ginger (*Zingiber officinale*) and turmeric (*Curcuma longa*) rhizomes against cadmium-induced nephrotoxicity in rats. *Journal of Oleo Science*, 67(10), 1339-1345. <https://doi.org/10.5650/jos.ess18115>
- Alkuraishy, H. M., Al-Gareeb, A. I., & Rasheed, H. A. (2019). Nephroprotective effect of curcumin (*Curcuma longa*) in acute nephrotoxicity in Sprague-Dawley rats. *Journal of Contemporary Medical Sciences*, 5(2), 122-124. <https://doi.org/10.22317/jcms.v5i2.580>
- Anadozie, S. O., Akinyemi, J. A., Agunbiade, S., Ajiboye, B. O., & Adewale, O. B. (2018). *Bryophyllum pinnatum* inhibits arginase II activity and prevents oxidative damage occasioned by carbon tetrachloride (CCl₄) in rats. *Biomed Pharmacotherapy*, 101, 8–13. <https://doi.org/10.1016/j.biopha.2018.01.156>

- Anderson, D. J., Zhou, J., Cao, D., McDonald, M., Guenther, M., Hasoon, J., et al. (2022). Ketamine-induced cystitis: A comprehensive review of the urologic effects of this psychoactive drug. *Health Psychology Research*, 10(3), 38247. <https://doi.org/10.52965/001c.38247>
- Andrade, A. W. L., Guerra, G. C. B., de Souza Araújo, D. F., de Araújo Júnior, R. F., de Araújo, A. A., de Carvalho, T. G., et al. (2020). Anti-inflammatory and chemopreventive effects of *Bryophyllum pinnatum* (Lamarck) leaf extract in experimental colitis models in rodents. *Frontiers in Pharmacology*, 11, 998. <https://doi.org/10.3389/fphar.2020.00998>
- Badro, D. A. (2023). Chronic kidney disease management in developing countries. In Y. M. Al-Worafi (Ed.), *Handbook of Medical and Health Sciences in Developing Countries* (pp. 1-10). Springer. https://doi.org/10.1007/978-3-030-74786-2_27-1
- Baker, J. R. (1945). *Cytological technique* (2nd ed.). London: Methuen.
- Basist, P., Zahiruddin, S., Khan, M. U., Gautam, G., Jan, B., Khan, M. A., et al. (2022). Metabolite profiling and nephroprotective potential of *Glycyrrhiza glabra* L. roots against cisplatin-induced nephrotoxicity in vitro and in vivo. *Iranian Journal of Basic Medical Sciences*, 25(11), 1286-1298. <https://doi.org/10.22038/IJBMS.2022.65478.14404>
- Ben-Azu, B., Aderibigbe, A. O., Ajayi, A. M., & Iwalewa, E. O. (2016). Neuroprotective effects of the ethanol stem bark extracts of *Terminalia ivorensis* in ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. *Pharmacology and Biology*, 54(12), 2871-2879. <https://doi.org/10.1080/13880209.2016.1190382>
- Bonsnes, R. W., & Taussky, H. H. (1945). On colorimetric determination of creatinine by the Jaffe reaction. *Journal of Biological Chemistry*, 158, 581-591.
- Boyer, N., Eldridge, J., Prowle, J. R., & Forni, L. G. (2022). Postoperative acute kidney injury. *Clinical Journal of the American Society of Nephrology*, 17(10), 1535-1545.
- Chan, E. O. T., Chan, V. W. S., Tang, T. S. T., Cheung, V., Wong, M. C. S., Yee, C. H., et al. (2022). Systematic review and meta-analysis of ketamine-associated uropathy. *Hong Kong Medical Journal*, 28(6), 466-474. <https://doi.org/10.12809/hkmj209194>
- Cheung, H. M., & Yew, D. T. W. (2019). Effects of perinatal exposure to ketamine on the developing brain. *Frontiers in Neuroscience*, 13, 138. <https://doi.org/10.3389/fnins.2019.00138>
- Choudhury, D., Autry, A. E., Tolias, K. F., & Krishnan, V. (2021). Ketamine: Neuroprotective or neurotoxic? *Frontiers in Neuroscience*, 15, 672526. <https://doi.org/10.3389/fnins.2021.672526>
- Daniel, I. E., Akpan, E. I., & Utam, E. C. (2020). Phytochemical evaluation, antioxidant, and antimicrobial activities of various extracts from leaves and stems of *Bryophyllum pinnatum*. *Nepal Journal of Biotechnology*, 8(1), 17-28. <https://doi.org/10.3126/njb.v8i1.30206>
- Das, K., Tiwari, R. K. S., & Shrivastava, D. K. (2010). Techniques for evaluation of medicinal plant products as antimicrobial agents: Current methods and future trends. *Journal of Medicinal Plants Research*, 4(2), 104-111.
- Demirkiran, H., Senoglu, N., Oksuz, H., Dogan, Z., Yuzbasioglu, F., Bulbuloglu, E., et al. (2019). The effects of different doses of ketamine on renal ischemia/reperfusion injury in rats. *Eastern Journal of Medicine*, 24(2), 194-199. <https://doi.org/10.5505/ejm.2019.48658>
- Dhumane, S., Naik, T., Shelke, M., Dukare, K., & Dhongade, K. (2024). Exploring the therapeutic potential: Phytochemistry and pharmacology of *Bryophyllum pinnatum*. *Journal of Drug Delivery and Therapy*, 14(2), 171-177. <https://doi.org/10.22270/jddt.v14i2.6282>
- Dibbur, V. S. (2021). Ketamine abuse in youngsters linked to kidney damage: Here is everything you should know. *The Economic Times: Healthworld*. <https://health.economictimes.indiatimes.com/news/industry/ketamine-abuse-in-youngsters-linked-to-kidney-damage-here-is-everything-you-should-know/87427561>
- Dighade, R., Ingole, R., Ingle, P., Gade, A., Hajare, S., & Ingawale, M. (2021). Nephroprotective effect of *Bryophyllum pinnatum*-mediated silver nanoparticles in ethylene glycol-induced urolithiasis in rats. *IET Nanobiotechnology*, 15(3), 266-276. <https://doi.org/10.1049/nbt2.12011>
- Doumas, B. T., Watson, W. A., & Biggs, H. G. (1971). Albumin standards and the measurement of serum albumin with bromocresol green. *Clinical Chimica Acta*,

- 31, 87-96. [https://doi.org/10.1016/0009-8981\(71\)90365-2](https://doi.org/10.1016/0009-8981(71)90365-2)
- Egunlusi, A. O., & Joubert, J. (2024). NMDA receptor antagonists: Emerging insights into molecular mechanisms and clinical applications in neurological disorders. *Pharmaceuticals*, 17(5), 639. <https://doi.org/10.3390/ph17050639>
- Ezquerro-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. (2018). Ketamine for the treatment of addiction: Evidence and potential mechanisms. *Neuropharmacology*, 142, 72-82. <https://doi.org/10.1016/j.neuropharm.2018.01.017>
- Geoffrion, L. (2024). Ketamine abuse: Addiction, effects, and treatment. American Addiction Centers. <https://americanaddictioncenters.org/ketamine-abuse>
- Hosomi, J. K., Facina, A. D. S., Simões, M. J., & Nakamura, M. U. (2022). Effects of *Bryophyllum pinnatum* administration on Wistar rat pregnancy: Biochemical and histological aspects. *Complementary Medicine Research*, 29(1), 35-42. <https://doi.org/10.1159/000517508>
- Hosten, A. O. (1990). BUN and creatinine. In H. K. Walker, W. D. Hall, & J. W. Hurst (Eds.), *Clinical methods: The history, physical, and laboratory examinations* (3rd ed., Chapter 193). Boston: Butterworths.
- Isirima, J. C., & Uahomo, P. O. (2023). *Acalypha wilkesiana* exhibits antihyperglycemic potentials and ameliorates damages to pancreas and spleen of diabetic rat model. *Saudi Journal of Biomedical Research*, 8(7), 83-94.
- Jang, M. Y., Shen, J. T., Geng, J. H., et al. (2017). Ketamine induced renal fibrosis in a ketamine addiction rat model. *Urological Science*, 28(3), 123-127. <https://doi.org/10.1016/j.urols.2016.12.004>
- Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., et al. (2013). Chronic kidney disease: Global dimension and perspectives. *Lancet*, 382(9888), 260-272. [https://doi.org/10.1016/S0140-6736\(13\)60687-X](https://doi.org/10.1016/S0140-6736(13)60687-X)
- Ji, D., & Karlik, J. (2022). Neurotoxic impact of individual anesthetic agents on the developing brain. *Children*, 9(11), 1779. <https://doi.org/10.3390/children9111779>
- Kasikara, H., Sungu, N., Arslan, M., Kucuk, A., Ozturk, L., Afandiyeva, N., et al. (2021). Repeated doses of ketamine affect the infant rat urogenital system. *Drug Design, Development and Therapy*, 15, 1157-1165. <https://doi.org/10.2147/DDDT.S285862>
- Lee, H. Y., Lee, G. H., Hoang, T. H., Kim, S. W., Kang, C. G., Jo, J. H., et al. (2022). Turmeric extract (*Curcuma longa* L.) regulates hepatic toxicity in a single ethanol binge rat model. *Heliyon*, 8(9), e10737. <https://doi.org/10.1016/j.heliyon.2022.e10737>
- Liu, B. C., Tang, T. T., Lv, L. L., & Lan, H. Y. (2018). Renal tubule injury: A driving force toward chronic kidney disease. *Kidney International*, 93(3), 568-579. <https://doi.org/10.1016/j.kint.2017.09.033>
- Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019). The role of NMDA receptors in Alzheimer's disease. *Frontiers in Neuroscience*, 13, 43. <https://doi.org/10.3389/fnins.2019.00043>
- Malek, M., & Nematbakhsh, M. (2015). Renal ischemia/reperfusion injury: From pathophysiology to treatment. *Journal of Renal Injury Prevention*, 4(2), 20-27. <https://doi.org/10.12861/jrip.2015.06>
- Manongi, N., Yoon, S. H., Luo, J. J., & Trivedi, P. (2022). Severe ketamine-induced uropathy associated with cholangiopathy requiring percutaneous nephrostomy. *Cureus*, 14(10), e30443. <https://doi.org/10.7759/cureus.30443>
- Maruna, R. F. L., & Trinder, P. (1958). Determination of serum sodium by the magnesium uranyl acetate. *Clinical Chimica Acta*, 2(1), 581-585.
- Monte, A. S., de Souza, G. C., McIntyre, R. S., et al. (2013). Prevention and reversal of ketamine-induced schizophrenia-related behavior by minocycline in mice: Possible involvement of antioxidant and nitric pathways. *Journal of Psychopharmacology*, 27(11), 1032-1043. <https://doi.org/10.1177/0269881113503506>
- Morgan, C. J., Curran, H. V., & Independent Scientific Committee on Drugs. (2012). Ketamine use: A review. *Addiction*, 107(1), 27-38. <https://doi.org/10.1111/j.1360-0443.2011.03576.x>
- Morin, L. G. (1974). Direct colorimetric determination of serum calcium with o-cresolphthalein complexon. *American Journal of Clinical Pathology*, 61(1), 114-117. <https://doi.org/10.1093/ajcp/61.1.114>
- Namadina, M. M., Yahuza, S., Haruna, H., Ibrahim, S., Balarabe, S., Abdullahi, N. M.,

- et al. (2020). Pharmacognostic and antioxidant activity of *Bryophyllum pinnatum* leaves. International Journal of Science and Global Sustainability, 6(2), 21–31.
- Nsengiyumva, V., Igiraneza, G., & Lameire, N. (2018). Definition and epidemiology of acute kidney injury. Rwanda Medical Journal, 75(2), 17-21.
- Ogregade, I. E., Ifenkwe, J. C., & Bartimaeus, E. A. (2024). Evaluating the nephroprotective and hepatoprotective effects of *Hypoestes rosea* in acetaminophen-induced toxicity in albino rats. Annals of Innovative Medicine, 2(2). <https://doi.org/10.59652/aim.v2i2.203>
- Ou, S. H., Wu, L. Y., Chen, H. Y., Huang, C. W., Hsu, C. Y., Chen, C. L., et al. (2020). Risk of renal function decline in patients with ketamine-associated uropathy. International Journal of Environmental Research and Public Health, 17(19), 7260. <https://doi.org/10.3390/ijerph17197260>
- Pahmi, K., & Sidratullah, M. (2023). Effect of Leafyflower (*Phyllanthus niruri* Linn.) treatment on kidney and uterus in sodium chloride-induced fibrotic rats. Bioscientia Medicina, 5(3), 263-267. <https://doi.org/10.32539/bsm.v5i3.187>
- Pandey, A., & Tripathi, S. (2014). Concept of standardization, extraction and prephytochemical screening strategies for herbal drug. Journal of Pharmacognosy and Phytochemistry, 2(5), 115-119.
- Salahdeen, H. M., & Yemitan, O. K. (2006). Neuropharmacological effects of aqueous leaf extract of *Bryophyllum pinnatum* in mice. African Journal of Biomedical Research, 9, 101-107.
- Selby, N. M., Anderson, J., Bungay, P., Chesterton, L. J., & Kolhe, N. V. (2008). Obstructive nephropathy and kidney injury associated with ketamine abuse. NDT Plus, 1(5), 310-312. <https://doi.org/10.1093/ndtplus/sfn054>
- Selvakumar, P. (2022). Phytochemical and pharmacological profile review of *Bryophyllum pinnatum*. Biomed Biotech Research Journal, 6(3), 295–301. https://doi.org/10.4103/bbrj.bbrj_126_22
- Shukla, A. B., Mandavia, D. R., Barvaliya, M. J., Baxi, S. N., & Tripathi, C. R. (2014). Evaluation of anti-urolithiatic effect of aqueous extract of *Bryophyllum pinnatum* (Lam.) leaves using ethylene glycol-induced renal calculi. Avicenna Journal of Phytomedicine, 4(3), 151–159.
- Shung-Lai, L., & Ma, W. K. (2021). Urological effects of ketamine abuse. IntechOpen. <https://doi.org/10.5772/intechopen.91283>
- Strous, J. F. M., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D., Lok, A., et al. (2022). Brain changes associated with long-term ketamine abuse: A systematic review. Frontiers in Neuroanatomy, 16, 795231. <https://doi.org/10.3389/fnana.2022.795231>
- Uahomo, P. O., & Isirima, J. C. (2024). Neuroprotective effects of *Bryophyllum pinnatum* against ketamine-induced neurotoxicity in Wistar rats: Neurochemical, oxidative stress, and histological investigation. International Neuropsychiatric Disease Journal, 21(6), 19-40. <https://doi.org/10.9734/indj/2024/v21i6452>
- Uahomo, P. O., Ibubeleye, V. T., Ezerioha, C. E., & Adheke, O. M. (2023). Sub-anesthetic dose of ketamine improves cognitive function and motor responses in Wistar rats. International Neuropsychiatric Disease Journal, 19(4), 29-42. <https://doi.org/10.9734/indj/2023/v19i4380>
- Vizgan, G., Huamán, M., Rychik, K., Edeson, M., & Blaivas, J. G. (2023). Ketamine-induced uropathy: A narrative systematic review of surgical outcomes of reconstructive surgery. BJUI Compass, 4(4), 377–384. <https://doi.org/10.1002/bco2.239384>
- Wandile, P. (2023). Complexity and management of chronic kidney disease. Open Journal of Nephrology, 13, 280-291. <https://doi.org/10.4236/ojneph.2023.133027>
- Wanjala, A. K., Oyugi, S. O., & Nyabola, A. M. (2023). Curcuma longa renal historestorative effects on sildenafil-induced nephrotoxicity among male albino rats. Anatomy Journal of Africa, 12(3), 2504-2509. <https://doi.org/10.4314/aja.v12i3.7>
- Weatherburn, M. W. (1967). Phenol hypochlorite reaction for determination of ammonia. Analytical Chemistry, 39, 971-974. <https://doi.org/10.1021/ac60252a045>
- Yadav, M., Gulkari, V. D., & Wanjari, M. M. (2016). *Bryophyllum pinnatum* leaf extracts prevent formation of renal calculi in lithiatic rats. Ancient Science of Life, 36(2), 90–97. https://doi.org/10.4103/asl.ASL_90_16
- Yahyaee, B., Babaei, H., Khojasteh, L., Arminfar, A., Jorjani, A., Jannati Toupanloo, K., et al. (2024). Histopathological study of the kidney tissue of neonatal rats born from

mothers receiving short-term and long-term ketamine injections. Journal of Guilan University of Medical Sciences, 32(4), 308–317.
<https://doi.org/10.32598/JGUMS.32.4.2089>
.1

Yoo, N., Thomas, S., Bender, M., & Cheng, X. J. C. (2024). A case of hepatotoxicity induced by therapeutic ketamine use for sedation. Case Reports in Critical Care, 2024, 8366034.
<https://doi.org/10.1155/2024/8366034>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2025): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/129155>